Developing a drug through the 505(b)(2) pathway can provide an important opportunity for pharmaceutical companies to build on existing knowledge while developing a product with meaningful differences from an already approved drug. However, the abbreviated nature of the pathway should not be mistaken for reduced responsibility for product quality. A well-designed CMC strategy remains essential to demonstrate that the proposed drug can be consistently manufactured and controlled throughout development and commercialization. Under section 505(b)(2), an applicant may rely in part on investigations that were not conducted by or for the applicant and for which the applicant does not have a right of reference or use. FDA describes the pathway as an NDA pathway rather than a generic-drug application under section 505(j). For developers, this distinction has important CMC implications. The development program must clearly explain what is being relied upon from existing information and what evidence is being generated specifically for the proposed product.

Why CMC Planning Matters Early

CMC considerations should begin well before the NDA. During the IND stage, FDA expects enough information to evaluate the identity, quality, purity, and strength of the investigational product and to assess whether manufacturing-related risks could affect clinical safety. Importantly, the amount of CMC information needed is phase-dependent and can vary with the formulation, study duration, and nature of the investigation. This makes a phase-appropriate CMC strategy particularly valuable for 505(b)(2) developers. At the early clinical stage, the focus should be on information necessary to support safe clinical investigation. As development advances, the CMC package should become increasingly comprehensive, addressing commercial manufacturing, analytical controls, specifications, stability, and process consistency. FDA has recently emphasized this approach for certain first-in-human Phase 1 INDs. Its current information states that some stability information, analytical method validation data, and non-safety-related process controls may generally be provided later in development. FDA estimates that these flexibilities can reduce development time for eligible FIH Phase 1 INDs by up to 12 months.

Connecting the Reference Product to the Proposed Product

One of the most important challenges in a 505(b)(2) CMC strategy is understanding the differences between the proposed product and the product or information being relied upon. A 505(b)(2) product may involve changes such as a different dosage form, strength, route of administration, formulation, delivery system, or other product characteristics. Each difference should be evaluated from a quality perspective. The sponsor needs to understand whether the change affects critical quality attributes, manufacturing controls, analytical testing, stability, or the evidence required to support the proposed product. This is where CMC and regulatory strategy must work together. A sponsor should not simply assume that information associated with an approved product automatically establishes the quality of the new product. Product-specific evidence may still be necessary.

Analytical Controls and Stability

Strong FDA CMC requirements extend to analytical procedures, specifications, impurity controls, and stability. Analytical methods should be appropriate for their intended use, while specifications should be scientifically justified and capable of controlling relevant quality attributes. Stability is equally important. The sponsor should develop a stability program capable of supporting proposed storage conditions and shelf life and should understand potential degradation pathways and changes in product quality over time. For a 505(b)(2) product, these issues can become especially important when formulation or manufacturing differences could influence degradation, impurity formation, dissolution, delivery, or other quality characteristics.

Manufacturing and Process Control Expectations

As the product moves toward commercialization, the CMC regulatory strategy should address the manufacturing process in sufficient detail to demonstrate consistency and control. This includes the drug substance, drug product, manufacturing operations, process controls, testing, packaging, and relevant facilities. Sponsors working with contract manufacturers should also establish clear responsibilities for quality systems, deviations, investigations, testing, change control, and regulatory documentation. FDA’s CMC framework applies to NDA products marketed under section 505(b)(2), including certain postapproval manufacturing changes. A common compliance risk is allowing the clinical and commercial manufacturing strategies to develop independently. Changes in formulation, manufacturing site, scale, equipment, or process can potentially create comparability concerns. Therefore, sponsors should maintain strong documentation and change-management processes throughout development.

Regulatory Developments to Watch

The regulatory environment surrounding abbreviated pathways continues to evolve. In August 2026, FDA issued a new draft guidance, Determining Whether to Submit an ANDA or a 505(b)(2) Application, intended to help applicants determine which pathway is appropriate. The draft revises FDA’s 2019 guidance and, if finalized, would replace it. Because it is currently a draft, it is not for implementation and represents FDA’s current thinking rather than binding requirements. This development reinforces the importance of making the pathway determination early. Choosing the appropriate regulatory route can influence development planning, data requirements, intellectual property considerations, CMC strategy, and the eventual marketing application.

Practical Approach for Sponsors

For companies developing a 505(b)(2) NDA, the most effective approach is to integrate CMC planning into the broader development strategy from the beginning. Sponsors should clearly define the product and its differences from the relied-upon information, establish appropriate controls for the drug substance and drug product, develop analytical and stability programs that evolve with development, and maintain consistency between clinical and commercial manufacturing plans. Early FDA interaction can also be valuable when sponsors face significant uncertainty regarding product differences, CMC data requirements, manufacturing changes, or the appropriate regulatory pathway. Resolving these questions earlier can help reduce costly delays during NDA review. 

Ultimately, the 505(b)(2) pathway can offer development efficiencies, but those efficiencies depend on a well-supported scientific and regulatory strategy. Strong pharmaceutical CMC strategy, disciplined documentation, appropriate analytical controls, and proactive regulatory planning can help sponsors move from IND development toward a more predictable NDA submission.